Despite strong revenue, the low P/S ratio may be due to less attractive future growth rates. Investors pay less for the stock, expecting limited growth rates to persist. Unless medium-term conditions improve, they will continue to limit the share price.
Despite recent positive returns from Uni-Bio Science Group, the market, as indicated by the P/S ratio, predicts this performance won't last. Current shareholders may remain optimistic, but the consensus appears to believe in continued limited growth rates, hence the devaluation of the stock.
聯康生物科技集團股票討論區
暫無評論